Rituximab, an Anti‐CD20 Monoclonal Antibody: History and Mechanism of Action - Pescovitz - 2006 - American Journal of Transplantation - Wiley Online Library
An analysis of Rituximab dose reduction & CD 19 monitoring
Rituximab in nephrology
Novel HDAC inhibitor Chidamide synergizes with Rituximab to inhibit diffuse large B-cell lymphoma tumour growth by upregulating CD20 | Cell Death & Disease
Far- and near-UV CD spectra of (a) Rituximab and (b) Etanercept... | Download Scientific Diagram
B-lymphocyte Antigen CD20 Epitope Peptide Fragment, Bound To Rituximab (Fab Fragment). Indications for Rituximab Include Leukemia Stock Illustration - Illustration of rheumatoid, cd20: 188464549
Update on the role of venetoclax and rituximab in the treatment of relapsed or refractory CLL - James D'Rozario, Samuel K. Bennett, 2019
Clinical review: Serious adverse events associated with the use of rituximab - a critical care perspective | Critical Care | Full Text
Anti-CD47 Antibody Synergizes with Rituximab to Promote Phagocytosis and Eradicate Non-Hodgkin Lymphoma: Cell
The proposed mechanisms of action for rituximab, a chimeric monoclonal... | Download Scientific Diagram
Rituximab - Wikipedia
Rituximab | Offarm
What is RITUXAN® (rituximab) for GPA and MPA?
Rituximab for the treatment of multiple sclerosis: a review | SpringerLink
anti-CD20 (Rituximab) - ACE Biolabs Antibody │ Chemical │ Enzyme
Efficacy and Toxicity of Rituximab in Multiple Sclerosis | Archives of Neuroscience | Full Text
Drug Insight: the mechanism of action of rituximab in autoimmune disease—the immune complex decoy hypothesis | Nature Reviews Rheumatology
Figure 1 from Rituximab (Anti-CD20 Monoclonal Antibody) – Ultimate or First Choice in Pemphigus? | Semantic Scholar
Rituximab Gains Expanded Approval in Pediatrics - Vasculitis Foundation
Overcoming resistance to rituximab in relapsed non-Hodgkin lymphomas by antibody-polymer drug conjugates actively targeted by anti-CD38 daratumumab - ScienceDirect
How a Third COVID Vaccine Dose Affects People Taking Rituximab
Frontiers | A Personalized Rituximab Retreatment Approach Based on Clinical and B-Cell Biomarkers in ANCA-Associated Vasculitis
